Genetic Ablation of Inositol 1,4,5-Trisphosphate Receptor Type 2 (IPR2) Fails to Modify Disease Progression in a Mouse Model of Spinocerebellar Ataxia Type 3

Spinocerebellar ataxia type 3 (SCA3) is a rare neurodegenerative disease caused by an abnormal polyglutamine expansion within the ataxin-3 protein (ATXN3). This leads to neurodegeneration of specific brain and spinal cord regions, resulting in a progressive loss of motor function. Despite neuronal death, non-neuronal cells, including astrocytes, are also involved in SCA3 pathogenesis. Astrogliosis is a common pathological feature in SCA3 patients and animal models of the disease. However, the contribution of astrocytes to SCA3 is not clearly defined. Inositol 1,4,5-trisphosphate receptor type 2 (IPR2) is the predominant IPR in mediating astrocyte somatic calcium signals, and genetically ablation of IPR2 has been widely used to study astrocyte function. Here, we aimed to investigate the relevance of IPR2 in the onset and progression of SCA3. For this, we tested whether IPR2 depletion and the consecutive suppression of global astrocytic calcium signalling would lead to marked changes in the behavioral phenotype of a SCA3 mouse model, the CMVMJD135 transgenic line. This was achieved by crossing IPR2 null mice with the CMVMJD135 mouse model and performing a longitudinal behavioral characterization of these mice using well-established motor-related function tests. Our results demonstrate that IPR2 deletion in astrocytes does not modify SCA3 progression.